Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers.

The aim of this study was to investigate the early outcome of Endostar combined with chemoradiotherapy for advanced cervical cancer. Fifty-two cases (FIGO IIb to IVa) were divided randomly into two groups, receiving chemoradiotherapy alone (CRT group) and Endostar combined with chemoradiotherapy (CRT+E group). For the patients in the CRT+E group, Endostar was administered daily with the dosage of 7.5 mg/m2, and cisplatin was administered weekly with the dosage of 20 mg/m2 during the radiation. The regimens lasted for 4 weeks with no difference in chemoradiotherapy between the two groups. The early outcome complete remission rate was 73.1%, partial remission rate was 23.1% and the total response rate was 96.2% in CRT+E group, a significnat improvement on the 34.6%, 42.3% and 76.9%, respectively, in the CRT group. One year survive rates were 100% and 84.6% in the CRT+E group and CRT groups, the difference being significant. Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.

• Publication year

  2012

• Venue

  Asian Pacific Journal of Cancer Prevention

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.7314/APJCP.2012.13.3.923PMID 22631672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study.

  2011cited by this paper
• Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.

  2011cited by this paper
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

  2011cited by this paper
• [Differential anti-tumor effects for various regimens of endostar plus cisplatin in ovarian cancer].

  2011cited by this paper
• Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model.

  2011cited by this paper
• [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].

  2011cited by this paper
• [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].

  2011cited by this paper
• Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.

  2011cited by this paper
• Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.

  2010cited by this paper
• [Endostar reduces the growth and metastasis by inhibiting angiogenesis and lymphangiogenesis in nude mouse models of human cervical cancer].

  2009cited by this paper
• Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice.

  2007cited by this paper
• Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells

  2005cited by this paper
• Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

  2004cited by this paper
• Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer.

  2004cited by this paper
• Influence of clinical and pathologic parameters on prognosis of cervical carcinoma in China

  2003cited by this paper
• Influence of Clinical and Pathologic Parameters on Prognosis of Cervical Carcinoma in China

  2003cited by this paper
• Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

  2000cited by this paper
• Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

  1999cited by this paper
• Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

  1999cited by this paper

• Molecular Targets of Cervical Cancer and Its Microenvironment: Advances in Treatment.

  2026cites this paper
• Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial

  2025cites this paper
• Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI

  2022cites this paper
• Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials

  2022cites this paper
• Endostar Synergizes with Radiotherapy to Inhibit Angiogenesis of Cervical Cancer in a Subcutaneous Xenograft Mouse Model.

  2022cites this paper
• Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer

  2021cites this paper
• Five-year survival rate analysis: the combination of fortnightly-administration of endostar and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer.

  2021cites this paper
• Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer

  2020cites this paper
• Combined microwave ablation and antiangiogenic therapy to increase local efficacy

  2020cites this paper
• Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.

  2019cites this paper
• The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

  2018cites this paper
• Efficacy of pEgr-1-endostatin combined with ionizing radiation on hypoxic conditions in nude mice bearing SKOV3 ovarian carcinoma

  2017cites this paper
• Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion

  2017cites this paper
• APJ Is Associated with Treatment Response in Gastric Cancer Patients Receiving Concurrent Chemoradiotherapy and Endostar Therapy

  2017cites this paper
• Ilkka Alahuhta THE MICROENVIRONMENT IS ESSENTIAL FOR OTSCC PROGRESSION

  2016cites this paper
• Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV

  2016cites this paper
• The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG

  2016cites this paper
• The microenvironment is essential for OTSCC progression

  2016cites this paper
• Monitoring Tumor Targeting and Treatment Effects of IRDye 800CW and GX1-Conjugated Polylactic Acid Nanoparticles Encapsulating Endostar on Glioma by Optical Molecular Imaging

  2015cites this paper
• Monitoring Tumor Targeting and Treatment Effects of IRDye 800CW and GX1-Conjugated Polylactic Acid Nanoparticles Encapsulating Endostar on Glioma by Optical Molecular Imaging.

  2015cites this paper
• Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

  2015cites this paper
• Critical Role of Aberrant Angiogenesis in the Development of Tumor Hypoxia and Associated Radioresistance

  2014cites this paper
• Anti-tumor Effect of Integrin Targeted 177Lu-3PRGD2 and Combined Therapy with Endostar

  2014cites this paper
• Contrast-enhanced ultrasound analysis of tissue perfusion in tumor-bearing mice following treatment with endostatin combined with radiotherapy

  2014cites this paper
• Effects of endostar combined multidrug chemotherapy in osteosarcoma.

  2013cites this paper
• Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer

  2013cites this paper
• Efficacy and safety of endostar® combined with chemotherapy in patients with advanced soft tissue sarcomas.

  2013cites this paper
• Long‐term results of a randomized, double‐blind, and placebo‐controlled phase III trial: Endostar (rh‐endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non‐small cell lung cancer

  2013cites this paper
• Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.

  2013cites this paper